| The role of macrophages in cancer development and therapy E Cendrowicz, Z Sas, E Bremer, TP Rygiel Cancers 13 (08), 1946, 2021 | 211 | 2021 |
| The multifaceted role of autophagy in cancer and the microenvironment H Folkerts, S Hilgendorf, E Vellenga, E Bremer, VR Wiersma Medicinal research reviews 39 (2), 517-560, 2019 | 173 | 2019 |
| Therapeutic potential of Galectin‐9 in human disease VR Wiersma, M de Bruyn, W Helfrich, E Bremer Medicinal research reviews 33 (S1), E102-E126, 2013 | 172 | 2013 |
| Targeted induction of apoptosis for cancer therapy: current progress and prospects E Bremer, G Van Dam, BJ Kroesen, L de Leij, W Helfrich Trends in molecular medicine 12 (8), 382-393, 2006 | 168 | 2006 |
| Mechanisms of translocation of ER chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity VR Wiersma, M Michalak, TM Abdullah, E Bremer, P Eggleton Frontiers in oncology 5, 7, 2015 | 165 | 2015 |
| Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats Y Wei, P Chen, M de Bruyn, W Zhang, E Bremer, W Helfrich BMC gastroenterology 10, 1-9, 2010 | 137 | 2010 |
| Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy E Bremer International Scholarly Research Notices 2013 (1), 371854, 2013 | 136 | 2013 |
| Target cell‐restricted and‐enhanced apoptosis induction by a scFv: sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2 E Bremer, J Kuijlen, D Samplonius, H Walczak, L de Leij, W Helfrich International journal of cancer 109 (2), 281-290, 2004 | 129 | 2004 |
| Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor … E Bremer, DF Samplonius, L van Genne, MH Dijkstra, BJ Kroesen, ... Journal of Biological Chemistry 280 (11), 10025-10033, 2005 | 125 | 2005 |
| Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial S Wang, Y Lin, X Xiong, L Wang, Y Guo, Y Chen, S Chen, G Wang, P Lin, ... Clinical Cancer Research 26 (18), 4921-4932, 2020 | 111 | 2020 |
| Target cell–restricted apoptosis induction of acute leukemic t cells by a recombinant tumor necrosis factor–related apoptosis-inducing ligand fusion protein with specificity … E Bremer, DF Samplonius, M Peipp, L van Genne, BJ Kroesen, GH Fey, ... Cancer research 65 (8), 3380-3388, 2005 | 106 | 2005 |
| Antibody-based fusion proteins to target death receptors in cancer M de Bruyn, E Bremer, W Helfrich Cancer letters 332 (2), 175-183, 2013 | 96 | 2013 |
| Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo M de Bruyn, AA Rybczynska, Y Wei, M Schwenkert, GH Fey, ... Molecular cancer 9, 1-14, 2010 | 87 | 2010 |
| on TRAIL for malignant glioma therapy? JMA Kuijlen, E Bremer, JJA Mooij, WFA Den Dunnen, W Helfrich Neuropathology and applied neurobiology 36 (3), 168-182, 2010 | 86 | 2010 |
| CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy FL Komdeur, MCA Wouters, HH Workel, AM Tijans, ALJ Terwindt, ... Oncotarget 7 (46), 75130, 2016 | 85 | 2016 |
| A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability B Ten Cate, E Bremer, M De Bruyn, T Bijma, D Samplonius, ... Leukemia 23 (8), 1389-1397, 2009 | 84 | 2009 |
| Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein J Stieglmaier, E Bremer, C Kellner, TM Liebig, B Ten Cate, M Peipp, ... Cancer Immunology, Immunotherapy 57, 233-246, 2008 | 80 | 2008 |
| Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects P Eggleton, E Bremer, JM Tarr, M de Bruyn, W Helfrich, A Kendall, ... Arthritis research & therapy 13, 1-15, 2011 | 76 | 2011 |
| Calreticulin, a therapeutic target? P Eggleton, E Bremer, E Dudek, M Michalak Expert Opinion on Therapeutic Targets 20 (9), 1137-1147, 2016 | 75 | 2016 |
| Exceptionally potent anti-tumor bystander activity of an scFv: sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells E Bremer, D Samplonius, BJ Kroesen, L van Genne, L de Leij, W Helfrich Neoplasia 6 (5), 636-645, 2004 | 75 | 2004 |
